The emergence of fusion proteins that express the ROS1kinase domainhas become a promising target in non-small-cell lung cancer (NSCLC).Although earlier kinase inhibitors effectively managed ROS1-positivetumors, the rise of point mutations, particularly those beyond thebinding pocket, has challenged the inhibitor efficacy. Here, ROS1 is linked to non-small cell lung carcinoma.